Introduction {#Sec1}
============

ASD is a group of increasingly recognised \[[@CR1]\] lifespan persistent \[[@CR2]\] neurodevelopmental disorders of early onset \[[@CR3], [@CR4]\] characterised by abnormalities in language, social interaction and a range of stereotyped and repetitive behaviours \[[@CR5]\]. The biological basis of ASD remains poorly understood. However, autism (the paradigmatic ASD) is both highly heritable \[[@CR6]\], and associated with alterations in both pre-natal brain development \[[@CR7]\] and post-natal brain structure \[[@CR8], [@CR9]\]. Despite this, little is known regarding the influence of specific genes on brain anatomy in ASD with the exception of the serotonin transporter \[[@CR10]\] and monoamine oxidase \[[@CR11]\] genes which contain functional genetic variants that have been associated with cortical volume in children with ASD.

A strong and as yet unexamined candidate gene for modulating brain anatomy in ASD is Brain Derived Neurotrophic Factor (BDNF) which plays a key role in neurogenesis, cortical lamination, synaptic plasticity, and neuron survival \[[@CR12]\]. Intracellular packaging and secretion of BDNF is altered by a common functional \[[@CR13], [@CR14]\] non-synonymous single nucleotide polymorphism (SNP) within the 5′ region of the gene (BDNF val66met) which codes for a valine to methionine substitution. In the healthy population, genotype at this polymorphism has been associated with differences in cortical plasticity \[[@CR15]\] and regional cortical volume (CV) \[[@CR16]--[@CR21]\] (see Table [1](#Tab1){ref-type="table"}). Many of the cortical areas where BDNF val66met genotype influences CV in typically developing individuals overlap with those where structural differences have been reported between people with ASD and typically developing controls. Table 1Studies in healthy controls relating BDNF val66met to corticalFirst AuthorYearSample SizeAge (years)GenderMeasureFindingsValValMetPezawas20046942M: 34 R: 18-60mixedVBMMet carriers - Reduced CV in bilateral inferior and middle frontal gyri, left precuneus and superior parietal lobule, right medial frontal, precentral, superior frontal, postcentral gyri. Val homozygotes - Reduced CV in right middle frontal and lingual gyri.Agartz20066630M: 42mixedAutomated lobar CVNo significant effect of genotypeNemoto20064168M: 36 R: 20-72mixedVBMMet carriers - reduced CV in left parahippocampal gyrus.Varnas20087331M: 42mixedCortical ThicknessTrend towards association between genotype and CV in left frontal (straight gyrus, transverse frontopolar, superior frontal) and right frontal (pars triangularis) cortices. No effect of genotype on regional CTSchofield20089659M: 32 R: 20-60mixedVBMNo effect of genotype in regional CV*Abbreviations*: *M* Mean, *R* Range, *VBM* Voxel Based Morphometry, *CV* Cortical Volume, *CT* cortical thickness

For example three independent studies \[[@CR16], [@CR17], [@CR19]\] have reported regional cortical CV reductions in BDNF met carriers compared to val homozygotes in regions such as the dorso-lateral and inferior frontal, superior parietal and precuneus cortices. These are cortical regions where our group \[[@CR22]\], and others \[[@CR23]\] that have shown structural differences between people with ASD and healthy controls.

Furthermore, all \[[@CR24]--[@CR28]\] but one \[[@CR29]\] of the studies examining BDNF measures in ASD report abnormalities. Autism Spectrum Disorder has been associated with (i) elevated serum BDNF in infancy \[[@CR24]\] childhood and adulthood \[[@CR25], [@CR26]\], (ii) elevated blood lymphocyte BDNF mRNA in young adults \[[@CR30]\], and (iii) increased basal forebrain BDNF levels in post-mortem samples of cerebral cortex \[[@CR28]\].

Therefore, it is possible that altered BDNF signalling in ASD contributes to the anatomical differences of people with ASD by disturbing the pathways through which the BDNF val66met polymorphism influences regional CV. It is not known however if the CV correlates of BDNF val66met genotype differ between people with ASD and typically developing controls. Therefore, we carried out a preliminary exploratory investigation in which we related BDNF val66met genotype to 33 regional measures of CV in 71 individuals -- 41 of whom had an ASD diagnosis (35 with Asperger syndrome, four with high-functioning autism and two with other pervasive developmental disorders), and 30 typically developing controls. Furthermore, in those regions where there were significant differences between people with ASD and controls in the relationship between BDNF val66met genotype and CV -- we also examined if these were accompanied by alterations in cortical thickness (CT) or surface area (SA). The volume of a cortical region is approximated by the product of the total surface area and the mean cortical thickness of that region.

Because these two sole determinants of CV reflect distinct evolutionary and developmental processes \[[@CR31], [@CR32]\] -- it is important to disambiguate their relative contribution to any differences in the CV correlates of BDNF val66met genotype in people with ASD and controls. For example, SA is influenced by division of progenitor cells in the embryological periventricular area and varies as a function of brain volume and cortical folding (gyrification). In contrast, CT is likely to reflect dendritic arborization/pruning within the grey matter \[[@CR33]\] or myelination at the grey/white matter interface \[[@CR34]\].

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

We included 41 subjects with ASD and 30 healthy controls. All people with ASD were recruited through a hospital-based national clinic and a university department specialising in the assessment of ASD with infrastructure support from the Medical Research Council United Kingdom Autism Imaging Multicentre Study (MRC UK A.I.M.S) program. All cases were diagnosed clinically with Asperger syndrome (*n* = 35), autism (*n* = 4), or Pervasive-Developmental Disorder-not otherwise specified (*n* = 2) according to DSM-IV criteria. Diagnoses were made by a team of senior clinicians trained in the Autism Diagnostic Interview-Revised (ADI-R) (Le Couteur et al. 1989) and the Autism Diagnostic Observation Schedule (ADOS-G) (Lord et al. 2000). Twenty-four of the participants with ASD also agreed to confirmation of clinical diagnosis using the ADI-R or ADOS. Typically developing healthy controls were recruited through advertisement in the community.

Participants in the study underwent structured physical and psychiatric examination (for the presence of a co-morbid DSM-IV Axis I or II disorder). Participants did not have a history of physical or psychiatric disorder affecting brain function (e.g., epilepsy or psychosis), or a genetic disorder putatively associated with autistic spectrum disorders (e.g., Fragile X syndrome). All participants had full-scale intelligence quotients above 70. All subjects (or guardians where applicable) gave informed and written consent.

There were no statistically significant differences in mean age between cases and controls or between BDNF val homozygotes and BDNF met carriers. Demographic and cognitive details for all participants are given in Table [2](#Tab2){ref-type="table"}. Table 2Subject characteristicsCharacteristicCASESCONTROLSNumber4130Male3426Age at scan in years Mean34.6427.5 Range12--6412--51Standard deviation12.5511.89FSIQ Mean104.58126.5 Range73--13583--155 Standard deviation17.2319.09Genotype BDNF Val Val3119 BDNF Met carrier1011

Genotyping {#Sec4}
----------

The BDNF val66met genotype was determined using a TaqMan allele specific assay method (Applied Biosystems) according to the manufacturer's protocols. Polymerase chain reaction (PCR) amplifications were performed on an ABI PRISM^®^ 7000 Sequence Detection System (Applied Biosystems) with the reaction mixture in a total volume of 2 μl, consisting of 5 ng of genomic DNA, 2 × Universal PCR Master Mix (ABGENE), 40× TaqMan SNP Genotyping Assay Mix (Applied Biosystems), and deionized H~2~O. After denaturing at 95°C for 15 min, 50 cycles of PCR were performed under the following conditions: 92°C for 15 s and 60°C for 90 s. All genotypes were reported with the allelic discrimination program using the Applied Biosystems Sequence Detection System (SDS).

Magnetic resonance imaging {#Sec5}
--------------------------

Brain MRIs were acquired using a GE Signa 1.5 T neuro-optimised MR system (General Electric, Milwaukee WI, USA). "Freesurfer" freeware (<http://surfer.nmr.mgh.harvard.edu/fswiki>) was used to derive models of the cortical sheet in each T1-weighted image and parcellate out the cortex into 33 regions. These well-validated \[[@CR35], [@CR36]\] and fully automated procedures have been extensively described elsewhere \[[@CR37], [@CR38]\], and we will only provide a brief description here. Firstly, a surface reconstruction was made for each scan \[[@CR39]\]. This involved intensity normalisation, the removal of extra-cerebral tissues using a "skull stripping" algorithm, and image segmentation using a connected components algorithm. The output of this stage is a single filled white-matter volume for each cerebral hemisphere. A surface tessellation was then generated for each white- matter volume by fitting a deformable template. The grey matter/CSF surface was also modelled using a similar process. Given explicit models for the white/grey and grey/CSF surfaces, the measure of absolute cortical thickness at any given point on the white/grey matter surface is then taken to be the shortest distance between that point and the grey/CSF surface. This measurement is made at approximately 150,000 points across each hemisphere for each scan.

In order to achieve automated parcellation of each individual cortical hemispheric sheet into 33 regions \[[@CR38]\], a probabilistic atlas was placed within a surface-based co-ordinate system to which each scan was aligned. Parcellation generated a measure of total CV, total SA and average CT for each sub-region within each hemisphere. For each sub-region values for left and right hemispheres were combined, resulting in a total of three measures (SA, CT and GV) for each of 33 sub-regions.

Statistical analyses {#Sec6}
--------------------

Analyses of covariance (ANCOVAs) were used to model the effects of Group (ASD vs controls), BDNF genotype (Val vs Met carriers) and the interaction of these two terms on regional measures of CV. In order to limit the number of statistical tests, we combined measures of CV for each of 33 cortical regions per hemisphere into total bilateral CV for that region. Given the exploratory nature of this analysis we adopted an uncorrected p value of 0.05. For those regions showing significant "Group by Genotype" interaction effects, we carried out further ANCOVA's for CT and SA in order to establish which of these parameters may be contributing to "Group-by-Genotype" effects for CV (again, applying an uncorrected p value of 0.05). Cortical volume, SA and CT were not transformed before being used as dependent variables in these analyses.

Within this cross-sectional dataset, we were not able to identify the non-linear age effects reported in much larger, longitudinal studies\[[@CR40]\]. Linear age effect were however seen and given the wide age-range of our sample, age was included as a co-variate to remove variance not related to our independent variables of interest. As there were no significant differences between groups in gender, or intracranial volume (ICV) -- we did not co-vary for these in analyses. Furthermore, the relationships between ICV and CV, SA/gyrification and CT are complex, non-linear \[[@CR41]\] and may differ with age and gender \[[@CR42]\].

Results {#Sec7}
=======

Neither group, genotype, not the interaction of these two terms was associated with total intracranial volume, total cortical volume, total cortical surface area or mean cortical thickness.

There was a significant "Group by Genotype" interaction for CV in six cortical areas - posterior cingulate, caudal anterior cingulate, rostral middle frontal, lateral orbitofrontal, pars orbitalis and pars triangularis. Further, within all of these regions, significant "Group by Genotype" interactions were also found for SA, but not CT (Table [3](#Tab3){ref-type="table"}). In order to determine how specific "Group-by-Genotype" interactions for SA were to those regions also showing interactions for CV, we next ran ANCOVAs for SA in all cortical regions. No other areas showed a "Group-by-Genotype" interaction for SA (results not shown but available). Table 3Results for analyses of covariance for regional cortical measuresREGIONMEASUREVOLUMESURFACE AREATHICKNESSGROUPBDNFG x BGROUPBDNFG x BGROUPBDNFG x BFpFpFpFpFpFpFpFpFpBankSTS4.820.031.990.161.590.21CaudAntCing*0.020.890.610.44****6.31**0.01****0.110.740.460.50****8.44**0.005***0.000.950.000.990.150.70CaudMidFr4.150.051.030.310.730.40Cuneus0.270.600.020.900.140.71Entorhinal0.300.590.270.600.010.91Fusiform2.970.090.180.670.920.34InfPar4.120.052.390.130.060.81InfTemp0.280.602.350.131.990.16IsthCing2.530.124.470.043.340.07LatOccip5.040.031.010.320.430.51LatOrbFr*0.500.480.230.63****5.25**0.03****0.490.490.230.63****5.25**0.03***0.510.480.270.610.160.69Lingual1.190.280.240.630.140.71MedOrbFr0.030.860.630.431.730.19MidTemp1.840.180.220.640.840.36Parahipp0.500.480.920.34**4.230.04***0.060.940.680.412.470.12*0.720.400.640.430.780.38Paracentral3.770.062.760.101.270.27ParsOperc0.800.370.720.401.050.31ParsOrbit*0.660.422.580.11****4.77**0.03****0.140.711.320.25****4.36**0.04***1.290.261.190.280.780.38ParsTriang*0.080.930.070.80****4.17**0.05****0.000.990.010.92****5.46**0.02***0.120.760.010.940.050.83PeriCalc1.410.240.150.700.460.50PostCentral0.970.330.000.990.020.90PostCing*0.520.480.560.46****4.16**0.05****0.280.600.280.60****7.40**0.008***0.900.370.590.440.350.56PreCentral3.060.090.420.520.00.35Precuneus3.480.071.450.232.330.13RostrAntCing0.200.661.400.240.270.61RostrMidFr*0.180.670.030.87****4.30**0.04****0.010.910.050.82****5.30**0.02***0.870.360.000.990.340.56SupFr1.230.271.820.180.890.35SupPar0.200.660.080.791.650.20SupTemp0.170.680.580.450.700.41SupraMarg0.260.623.330.070.390.54FrontalPole0.030.870.140.710.070.80TempPole0.070.790.820.390.510.48TransvTemp0.660.421.840.181.110.30

In all six regions "Group by Genotype" interactions for both CV and SA reflected the same phenomenon -- lower CV/SA in control BDNF met allele carriers compared to control BDNF val homozygotes, but higher CV/SA in ASD BDNF met allele carriers as compared to ASD BDNF val homozygotes. The same pattern was seen in all six regions and is illustrated in Fig. [1](#Fig1){ref-type="fig"} using the caudal anterior cingulated as an example. Fig. 1Caudal anterior and posterior cingulate CV and SA by Group and BDNF genotype. Bars represent 95% confidence intervals for mean CV/SA

Discussion {#Sec8}
==========

The results from our exploratory study suggest that the relationship between cortical anatomy and BDNF genotype may differ between people with ASD and typically developing controls. Given the preliminary nature of our investigation we did not correct for multiple comparisons, and so replication is required. Nevertheless, our findings do lead to testable hypotheses.

Firstly, rather than being generalised, "Group-by-Genotype" interactions may be most marked in particular cortical regions, i.e the caudal anterior cingulate, posterior cingulate, rostral middle frontal, lateral orbitofrontal, pars orbitalis and pars triangularis. These regions are not scattered across the cortex, but describe two larger contiguous frontal areas -- one medial and one lateral.

Secondly, many of the cortical regions where we identified "Group-by-Genotype" interactions for CV/SA overlap with those where BDNF has been shown to modulate CV in typically developing by structural MRI \[eg in the medial, middle and inferior frontal \[[@CR16], [@CR17], [@CR19]\]\], and N-acetylaspartate levels (a marker of neuronal integrity) in healthy controls by Magnetic Resonance Spectroscopy \[anterior cingulate \[[@CR43]\]\]. In our sample the relationship between CV and BDNF val66met genotype in controls was in the same direction and similar frontal distribution as that reported in other samples of typically developing individuals \[[@CR16], [@CR17]\]. That is in controls CV was reduced in BDNF met allele carriers compared to BDNF val allele homozygotes. This relationship was reversed in people with ASD. Furthermore, cortical regions where we identified "Group-by-Genotype" interactions for CV/SA also overlap with those where compared to controls, people with ASD have been reported as showing alterations in CV \[[@CR23]\], cortical folding \[[@CR44]\] and magnetic resonance spectroscopy measures of neuronal integrity \[anterior cingulate \[[@CR45]\]\]. This suggests that differences in cortical structure between people with ASD and typically developing controls may be due to differences in BDNF val66met genotype frequency and/or function.

Thirdly, in those (and only those) regions showing significant "Group x Genotype" interactions for CV, we also found significant "Group x Genotype" interactions for SA, but not CT. This suggests that the CV findings are driven by "Group x Genotype" interactions for SA. The SA within a given cortical region may be altered in three ways; (i) alterations in radial brain size, (ii) displacement of the landmarks (eg sulcal landmarks) used to define regional boundaries, or (ii) increased gyrification of the cortical sheet within unaltered regional boundaries.

We did not identify any "Group-by-Genotype" interactions for intracranial volume or total cerebral SA (data not shown but available), which argues against the first of these explanations. The remaining two explanations are compatible with existing reports of altered sulcal positioning \[[@CR46]\] and gyrification \[[@CR47]\] in people with ASD compared to controls. As both of these cortical characteristics can be quantified from MRI scans -- their relative contributions to putative differences in the SA correlates of BDNF val66met genotype between people with ASD and controls can be directly examined in future work.

The mechanisms that could underlie differences between people with ASD and controls in the CV/SA correlates of BDNF val66met genotype are unclear. Such differences could be due to abnormal BDNF signalling in ASD causing disruption of the pathways through which the BDNF val66met polymorphism might influence cortical structure during typical development such as neuronal migration \[[@CR48]\] and/or experience dependent plasticity \[[@CR49]\]. Alternatively, our findings may not be due to abnormal BDNF signalling in ASD *per se*, but reflect the fact that brain structure is so atypical in ASD that the subtle differences accounted for by any given single genetic polymorphisms are "drowned out" (Raznahan et al, in press). A further possibility is that due to dysfunction within molecular pathways that interact with BDNF to influence brain development -- the typical downstream effects of differences in BDNF signalling due to val66met genotype are not seen in ASD. Autism Spectrum Disorder has been associated with reports of abnormalities within several discrete molecular systems that all share the feature of directly impacting on or interacting with BDNF transcription and function. These include serotonin (5HT) \[[@CR50], [@CR51]\], Calcium-dependent activator protein for secretion 2 (CAPS2) \[[@CR52], [@CR53]\], methyl-CpG binding protein 2 (MeCP2) \[[@CR14]\], and Jumonji AT-rich interactive domain 1C (JARID1C) \[[@CR54]\].

Our study has several limitations. Firstly, our sample size is relatively small. Our study does however represent the first examination of the relationship between BDNF and brain anatomy in ASD, and is equivalent in sample size to some of the smaller studies that have been published to date on BDNF vall66met and brain structure in typically developing controls \[[@CR55], [@CR56]\]. Secondly we were not able to obtain ADI-R/ADOS confirmation of clinical ASD diagnosis in all volunteers in our ASD group. However, this confirmation was available for the majority of people with ASD, and all ASD diagnoses were made by a multidisciplinary team trained in the ADI-R and ADOS. Thirdly, almost all participants with ASD in our study had a diagnosis of Asperger syndrome, and all had a FSIQ greater than 70. Further studies in diagnostically homogeneous samples of people with other ASD diagnoses and cognitive profiles will be required to establish the generalisability of our findings across the autism spectrum. Fourthly, people with ASD and controls differed significantly in general cognitive ability. Although this means that our findings may be driven my differences in FSIQ rather than ASD diagnosis *per se,* the strong association between ASD and learning disability complicates the issue of matching for IQ in study design \[[@CR57]\]. Furthermore, in our sample, FSIQ did not correlate with any of the regional cortical measures showing group-by-genotype interactions. Fifthly, because our sample covered a wide age-range, we co-varied for age in all analyses and were not therefore able to directly model possible "Group-by-Genotype-by-Age" effects on cortical anatomy. The age range of our sample and the predominance of individuals with Asperger syndrome diagnoses may also account for the fact that we did not observe the increased cortical volumes commonly reported in autism \[[@CR58], [@CR59]\]. Finally, as our sample included both males and females we were not able to determine the influence of gender on our findings.

In summary, our results provide preliminary evidence that in medial and lateral frontal cortices the relationship between BDNF val66met genotype and cortical volume is not the same in people with ASD as it is in typically developing populations. This may be due to differences between people with ASD and typically developing populations in either (i) BDNF val66met genotype frequencies, or (ii) the mechanisms linking this genetic polymorphism to regional variations in cortical surface area.
